Navigation Links
Celling Biosciences Received CE Mark Approval for ART PRP and ART BMC Systems
Date:6/16/2017

With an aging global population and rising dangers of opioid addiction and complications, demand for platelet-rich plasma and bone marrow concentrate based treatments has been steadily rising in the United States. According to the Global Regenerative Medicine Market 2016-2020 report, the specialty of regenerative medicine is forecasted to grow at a CAGR of 20.7%. Hank Brown, Celling Biosciences Executive Vice President of Sales, stated, “The CE Mark approval allows the company to respond to the growing opportunity in international markets, particularly within Europe, so this achievement is an important milestone in the company’s sales history and a strategic step in the company’s continued growth.”

The ART PRP and ART BMC are class-leading, sterile-packaged disposable devices that are used to concentrate a sample of a patient’s blood or bone marrow into their subcomponents through centrifugation. The concentration process takes less than 30 minutes at point-of-care and is often done on an outpatient basis depending on the procedure being performed. As peer-reviewed and presented at the Tissue Engineering and Regenerative Medicine International Society Annual Meeting (Sept 2015, Boston, MA), the ART BMC and ART BMC Plus devices consistently recovers 90% of concentrated autologous stem and progenitor cells, platelets, and growth factors – performance that is unrivaled in the world.

Also, unique to Celling Biosciences, the ART BMC and ART PRP systems have an optional, proprietary integrated filter system which allows physicians to further concentrate the patient’s platelet-rich plasma (PRP) or platelet-poor plasma (PPP) without any additional sterile breaks. In vitro studies have shown the filter system’s ability to concentrate proteins like alpha-2-macroglobulin (A2M), interleukin 1 receptor antagonist protein (IRAP), and fibrinogen.

Physicians can utilize the components of their choice to treat various orthopedic applications, employing ART PRP or ART BMC devices on average once every 42 minutes in the United States. The Celling Biosciences international business development team believes this level of usage will more than quadruple in the next year now that the European market is open for the ART family of products.

Kevin Dunworth, Celling Biosciences Founder and CEO, commented, “As the only company on the market with a cell-centric approach to all of our product lines, the development and commercialization of our proprietary ART PRP and ART BMC systems have been years in the making. Today is a proud moment for our company as we expand into the European market.”

About Celling Biosciences:
As the innovative leader in regenerative medicine, Celling Biosciences collaborates with physicians and scientists to develop the most sophisticated technologies and techniques for maximizing the collection, concentration, and delivery of autologous blood and bone marrow aspirate.

Read the full story at http://www.prweb.com/releases/2017/06/prweb14432785.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Adept Sound Has Announced the Market Launch of Innovative New Noise Cancelling Silicone Ear Plugs
2. Celling Biosciences Announces New Location in Austin, Texas
3. ACEA Biosciences, Inc. to be featured in Upcoming Episode of Innovations with Ed Begley, Jr.
4. INDIGO Biosciences Now Offers PXR
5. Sharp Edge Labs and Creagen Biosciences Enter Drug Discovery Collaboration
6. Wayne State opens new $93 million biosciences center aimed at eliminating health disparities in Detroit
7. GD Biosciences Announces Availability of the PULs Cardiac Test in India as Part of International Expansion
8. Vortex Biosciences Announces Publication in Oncotarget That Demonstrates the Value of Combining CTCs and cfDNA in Assessing Cancer Patient Disease
9. Vortex Biosciences Selected as Finalist for 2017 SLAS Innovation Award
10. Pierian Biosciences Names Mark S. Gelder, MD as Chief Medical Officer
11. Vortex Biosciences Announces Publication in Nature Communications Describing the First Single Cell Western Blot for Circulating Tumor Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
Breaking Medicine Technology: